Hemp/CBD ComplianceHemp and CBD Supplement Federal-State Compliance Framework
A comprehensive guide to the regulatory landscape of hemp-derived cannabinoids, navigating USDA production rules, FDA enforcement positions, and state-level requirements.

On this page · 9 sections
- 1The Multi-Layered Challenge of Hemp and CBD Compliance
- 2The 2018 Farm Bill: The 0.3% THC Threshold
- 3USDA Oversight and the Domestic Hemp Production Program
- 4The FDA's Stance: CBD in Foods and Supplements
- 5The Regulatory Patchwork: State-Level Variation
- 6Testing and Sampling: Ensuring Quality and Potency
- 7Labelling, Claims, and Misbranding Risks
- 8International Context: UK and EU Novel Foods
- 9Building a Robust Quality Management System (QMS)
How does Hemp/CBD Compliance apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01The Multi-Layered Challenge of Hemp and CBD Compliance
The legal status of hemp and its derivatives, most notably cannabidiol (CBD), is one of the most complex regulatory puzzles in modern manufacturing. Since the passage of the 2018 Farm Bill, hemp has been removed from the Controlled Substances Act (CSA), transforming it from a prohibited substance into an agricultural commodity. However, this removal did not create a regulatory vacuum or a free-for-all market. Instead, it triggered a multi-agency oversight framework involving the United States Department of Agriculture (USDA), the Food and Drug Administration (FDA), and a diverse patchwork of state-level authorities.
For manufacturers, 'compliance' in this sector is not a static destination but a continuous process of alignment with evolving rules. A product that meets USDA agricultural standards might still be considered 'adulterated' or 'misbranded' by the FDA if marketed as a dietary supplement. Similarly, a product that is legal under the laws of one state may be prohibited for sale in another due to differing definitions of 'Total THC' or specific labelling mandates. Navigating this landscape requires a deep understanding of the statutory definitions, testing methodologies, and enforcement priorities that define the hemp economy.
02The 2018 Farm Bill: The 0.3% THC Threshold
The Agricultural Improvement Act of 2018 (commonly known as the 2018 Farm Bill) is the foundational document for the modern hemp industry. It established a legal distinction between 'hemp' and 'marijuana' based on the concentration of delta-9 tetrahydrocannabinol (THC). Under the law, hemp is defined as the plant Cannabis sativa L. and any part of that plant, including the seeds and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 THC concentration of not more than 0.3 percent on a dry weight basis.
This 0.3% threshold is the 'bright line' of legality. Any cannabis plant or product that exceeds this limit is technically marijuana and remains a Schedule I controlled substance under federal law. This definition places immense pressure on manufacturers to ensure that their extraction and concentration processes do not inadvertently spike the THC levels above the legal limit. Even if the starting biomass is compliant, the process of extracting CBD often concentrates THC alongside it, requiring remediation steps to bring the final extract back into alignment with the 0.3% rule.
The 'Dry Weight' Requirement
The requirement that the 0.3% limit be measured on a 'dry weight basis' is a critical technical detail. Moisture content can significantly alter the weight of the plant material; therefore, testing laboratories must either dry the sample before testing or use a mathematical conversion to account for moisture. This ensures that the THC concentration is measured accurately across different harvests and environmental conditions.
03USDA Oversight and the Domestic Hemp Production Program
While the Farm Bill legalised hemp, it also mandated that the USDA establish a national regulatory framework for its production. The USDA's Final Rule, which took effect in early 2021, outlines the requirements for state and tribal hemp programs, as well as a federal plan for producers in jurisdictions that do not have their own USDA-approved plans.
Key components of the USDA program include:
- Land identification: Producers must provide exact GPS coordinates for all hemp production areas.
- Sampling and testing: Samples must be collected by a USDA-approved sampler within 30 days before harvest and tested at a DEA-registered laboratory.
- Total THC calculation: USDA requires testing to account for the conversion of tetrahydrocannabinolic acid (THCA) into delta-9 THC through a process called decarboxylation. The 'Total THC' reported must be the sum of delta-9 THC and (0.877 x THCA).
- Disposal of non-compliant plants: Plants that test above 0.3% delta-9 THC must be disposed of according to specific protocols, often involving law enforcement or DEA-registered reverse distributors.
The USDA framework also introduces the concept of a 'negligent violation.' If a producer's hemp tests above 0.3% but below 1.0% (a threshold that has been adjusted in recent years), it is considered a mistake rather than a criminal act, provided the producer made reasonable efforts to grow compliant hemp. However, three negligent violations in a five-year period can result in a suspension of the producer's license.
04The FDA's Stance: CBD in Foods and Supplements
Perhaps the most significant source of friction in the industry is the discrepancy between the Farm Bill's legalisation of hemp derivatives and the FDA's interpretation of the Federal Food, Drug, and Cosmetic (FD&C) Act. The FDA maintains that CBD cannot be marketed as a dietary supplement or added to food intended for humans or animals.
This position is based on the 'drug exclusion' provisions of the FD&C Act (Section 201(ff)(3)(B)). These provisions state that a substance cannot be marketed as a dietary supplement or food if it has been approved as a new drug or has been the subject of substantial clinical investigations that have been made public, unless the substance was marketed as a food or supplement *before* the drug investigations began. Because CBD is the active ingredient in the FDA-approved drug Epidiolex (used to treat rare forms of epilepsy), and because the FDA concluded that CBD was not marketed as a food or supplement prior to those investigations, the exclusionary clause applies.
Despite this federal prohibition, the CBD market has flourished, leading to what some call a period of 'enforcement discretion.' The FDA has primarily focused its enforcement actions on companies making 'egregious' health claims—such as claiming CBD can treat cancer, COVID-19, or Alzheimer's. However, the agency continues to state that the current regulatory framework is not adequate for CBD and has called on Congress to create a new pathway for these products.
05The Regulatory Patchwork: State-Level Variation
In the absence of clear federal regulations for finished CBD products, states have stepped in to fill the void, creating a complex 'patchwork' of laws. This variation makes interstate commerce exceptionally difficult for manufacturers.
Some states, like Colorado and California, have passed laws explicitly allowing CBD to be added to foods and supplements, provided certain quality and labelling standards are met. Other states have adopted the FDA's restrictive stance, effectively banning the sale of CBD-infused ingestibles. Furthermore, states differ on:
- THC limits: While the federal limit is 0.3% delta-9 THC, some states apply a 0.3% limit to 'Total THC' (Delta-9 + THCA).
- Labelling requirements: Many states require a QR code on every label that links directly to the Certificate of Analysis (CoA) for that specific batch.
- Age restrictions: Some states limit the sale of CBD products to individuals over 18 or 21.
- Retail licenses: Certain jurisdictions require retailers to obtain a specific permit to sell hemp-derived products.
For a national brand, this means that a single product formulation and label may not be legal in all 50 states. Manufacturers must often create state-specific stock-keeping units (SKUs) or adopt the 'highest common denominator' approach, meeting the strictest state requirements in every product they make.
06Testing and Sampling: Ensuring Quality and Potency
Accurate testing is the heartbeat of hemp compliance. Because the difference between a legal agricultural product and a controlled substance is only a few tenths of a percentage point of THC, the precision of laboratory methods is paramount. A Certificate of Analysis (CoA) is the document of record that proves a batch meets the required specifications.
Compliant testing protocols typically include:
- Potency Testing: Quantifying the levels of CBD, THC, and other cannabinoids. This is usually done via High-Performance Liquid Chromatography (HPLC).
- Pesticide Screening: Ensuring the hemp was grown without prohibited chemicals.
- Heavy Metal Analysis: Hemp is a bioaccumulator, meaning it readily absorbs metals like lead, arsenic, and mercury from the soil.
- Residual Solvent Testing: If chemical solvents like ethanol or CO2 were used in the extraction process, the final product must be tested to ensure no harmful residues remain.
- Microbial Testing: Checking for yeast, mould, E. coli, and Salmonella.
A major challenge in the industry is 'lab shopping,' where manufacturers seek out laboratories that provide the most favourable (i.e., highest CBD or lowest THC) results. Regulatory bodies are increasingly cracking down on this practice by requiring labs to be ISO 17025 accredited and by standardising the 'Measurement of Uncertainty' (MU) that must be reported alongside test results.
07Labelling, Claims, and Misbranding Risks
Under the FD&C Act, a product is 'misbranded' if its labelling is false or misleading in any particular way. In the hemp industry, misbranding risks usually fall into two categories: inaccurate cannabinoid content and unproven health claims.
The 'Truth in Labelling' Problem
Studies have shown that a significant percentage of CBD products on the market contain significantly more or less CBD than stated on the label. Some products have even been found to contain illegal levels of THC despite 'THC-free' claims. To mitigate this, many states now require specific label elements, including:
- A clear statement of the amount of CBD and THC per serving.
- A batch or lot number that corresponds to the production records.
- An expiration date or 'best by' date.
- A QR code or URL linking to the batch-specific CoA.
The Danger of Therapeutic Claims
The FDA is particularly sensitive to 'therapeutic' or 'health' claims. A claim is anything that suggests a product can diagnose, treat, cure, or prevent a disease. Even subtle phrasing like 'supports healthy inflammatory response' or 'relieves anxiety' can be flagged as an illegal drug claim if the FDA determines the intent is to market the product as a treatment for a condition. Companies must rely on 'structure/function' claims, which are much more limited in scope, and even these are legally precarious for CBD given the FDA's current position.
08International Context: UK and EU Novel Foods
For manufacturers looking to export hemp products, the regulatory landscape changes again. In the European Union (EU) and the United Kingdom (UK), CBD is generally classified as a 'Novel Food.'
A Novel Food is defined as a food that was not consumed to a significant degree by humans in the region before May 15, 1997. Because CBD was not a common dietary component before this date, it must undergo a rigorous safety assessment and receive authorisation from the European Food Safety Authority (EFSA) or the UK Food Standards Agency (FSA) before it can be legally sold.
In the UK, the FSA established a 'public list' of CBD products that were on the market before a specific cut-off date and had submitted valid novel food applications. Only products on this list are allowed to remain on the market while their applications are being processed. This represents a more structured, albeit slow, pathway to legality compared to the current situation in the United States.
It is important to note that the EU and UK also have their own THC limits, which are often stricter than the US 0.3% limit. For example, some jurisdictions may require finished products to contain less than 1mg of THC per container to avoid being classified as a controlled substance.
09Building a Robust Quality Management System (QMS)
Given the high stakes of hemp compliance, 'best effort' documentation is no longer sufficient. Successful manufacturers are adopting Quality Management Systems (QMS) and Good Manufacturing Practices (GMP) traditionally reserved for the pharmaceutical and dietary supplement industries. While the FDA may not yet recognise CBD as a supplement, following the GMP standards outlined in 21 CFR 111 (for supplements) or 21 CFR 211 (for pharma) is the best way to demonstrate a commitment to consumer safety and product consistency.
A compliant hemp QMS should include:
- Vendor Qualification: Verifying that hemp suppliers are USDA-compliant and that their biomass meets your specs.
- Standard Operating Procedures (SOPs): Documenting every step of the extraction, refinement, and packaging process.
- Batch Records: Capturing real-time data for every lot to ensure traceability from 'seed to shelf.'
- Deviation Management: Investigating any instances where a batch fails to meet specifications (e.g., a THC spike) and documenting the corrective action taken.
- Stability Testing: Providing evidence that the cannabinoid content remains accurate throughout the product's shelf life.
In the end, compliance is not just about avoiding fines; it is about building brand trust. In a crowded and often suspicious market, the ability to provide transparent, verifiable evidence of quality is a powerful competitive advantage.
Frequently asked questions
Q.Is CBD federally legal in the United States?+
The answer is nuanced. The 2018 Farm Bill legalised the production of hemp and its derivatives, provided they contain no more than 0.3% delta-9 THC. However, the FDA still maintains that CBD cannot be legally added to food or marketed as a dietary supplement. Therefore, while the substance itself is no longer a controlled substance, the way it is sold and marketed may still be illegal under the FD&C Act.
Q.What is the difference between Delta-9 THC and Total THC?+
Delta-9 THC is the primary psychoactive component of cannabis. THCA is the acidic precursor to Delta-9 THC. When heated, THCA converts to Delta-9 THC. Many regulatory bodies, including the USDA, require testing for 'Total THC,' which is calculated as (Delta-9 THC + 0.877 * THCA). This provides a more accurate picture of the potential potency of the product.
Q.Can I sell my CBD products in every state?+
Not necessarily. State laws regarding CBD vary widely. Some states allow all hemp-derived products, some allow only topical products, and others ban CBD-infused foods and drinks. Manufacturers must carefully review the laws of each state where they intend to sell their products to ensure they meet all local requirements for labelling, testing, and licensing.
Q.What does 'Novel Food' mean for CBD in the UK and EU?+
Novel Food status means that CBD is considered a 'new' food ingredient that lacks a history of safe consumption before 1997. Consequently, CBD products must undergo a comprehensive safety evaluation by the FSA (in the UK) or EFSA (in the EU). Only products that have been authorised or are in the authorisation process (and appear on the FSA's public list) can be legally sold.
Primary sources
Further reading
- 21 CFR Part 111The FDA's Current Good Manufacturing Practice (cGMP) requirements for dietary supplements.
- EU Novel Food Regulation 2015/2283Understanding the regulatory framework for new food ingredients in the European Union.
- UK FSA Novel Food GuidancePost-Brexit requirements for marketing CBD and other novel ingredients in the UK.
Want to see how Hemp/CBD Compliance could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
